SHIFTBIO CEO Gi-hoon Nam met with Pascal Daloz, CEO of Dassault Systèmes, and Woonsung Jung, Managing Director, Dassault Systèmes Korea, in Seoul to discuss deepening collaboration. Over the past three years, SHIFTBIO has actively applied Dassault’s 3DEXPERIENCE platform to accelerate the design and validation of our Natural Nanoparticle (NNP) drug delivery platform. This collaboration has reduced trial and error in discovery and strengthened our ability to translate science into real-world therapeutic opportunities.

At the meeting, both sides reaffirmed a shared vision of combining AI-powered design with digital platforms to de-risk the development of next-generation therapeutics. SHIFTBIO has also been invited to speak at Dassault’s upcoming Science in the Age of Experience event in Boston this October, engaging with global pharma leaders, regulators, and innovators.

Together, SHIFTBIO and Dassault aim to pioneer a new paradigm in advanced therapeutics, making innovation more accessible and impactful for patients worldwide!